Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: Dual agonists for human peroxisome proliferator-activated receptor α and δ

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 4, 2006, Pages 771-774

  Kasuga, Jun Ichi ^a   Hashimoto, Yuichi ^a   Miyachi, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Metabolic syndrome; PPAR ; PPAR ; Reductive amide alkylation

Indexed keywords

2 ETHYLPHENYLPROPANOIC ACID; OXAZOLIDINONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHENYLPROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; CHIRALITY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; ENANTIOMER; HUMAN;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; PHENYLPROPIONATES; PPAR ALPHA; PPAR DELTA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 30344435617     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.029     Document Type: Article

References (18)

1. D. Porte Jr., and M.W. Schwartz Science 272 1996 699
2. B. Staels, and J. Auwerx Curr. Pharm. Des. 3 1997 1
3. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke J. Med. Chem. 43 2000 527
4. A. Okuno, H. Tamemoto, K. Tobe, K. Ueki, Y. Mori, K. Iwamoto, K. Umesono, Y. Akanuma, T. Ujiwara, H. Horikoshi, Y. Yazaki, and T. Kadowaki J. Clin. Invest. 101 1998 1354
5. R. Mukherjee, L. Jow, D. Noonan, and D.P. McDonnell J. Steroid Biochem. Mol. Biol. 51 1994 157
6. P.J. Brown, D.A. Winegar, K.D. Plunket, L.B. Moore, M.C. Lewis, J.G. Wilson, S.S. Sundseth, C.S. Koble, Z. Wu, J.M. Chapman, J.M. Lehmann, S.A. Kliewer, and T.M. Willson J. Med. Chem. 42 1999 3785
7. Nomura, M.; Takahashi, Y.; Tanase, T.; Miyachi, H.; Ide, T.; Tsunoda, M.; Murakami, K.; PCT Int. Appl. WO 00/75103.
8. M. Nomura, T. Tanase, T. Ide, M. Tsunoda, M. Suzuki, H. Uchiki, K. Murakami, and H. Miyachi J. Med. Chem. 46 2003 3581
9. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, E. Chao, D. Goreham, M.L. Sierra, C. LeGrumelec, H.E. Xu, V.G. Montana, M.H. Lambert, T.M. Willson, W.R. Oliver Jr., and D.D. Sternbach Bioorg. Med. Chem. Lett. 13 2003 1517
10. H. Lim, R.A. Gupta, W.G. Ma, B.C. Paria, D.E. Moller, J.D. Morrow, R.N. DuBois, J.M. Trzaskos, and S.K. Dey Genes Dev. 13 1999 1561
11. Kasuga, J.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Bioorg. Med. Chem. Lett. 2005, accepted for publication.
12. M. Nomura, T. Tanase, and H. Miyachi Bioorg. Med. Chem. Lett. 12 2002 2101
13. 79Br (M + H) 460.1132, found 460.1161. This compound was used without further purification.
14. D. Dube, and A.A. Scholte Tetrahedron Lett. 40 1999 2295
15. D -68.1 (c = 0.356, MeCN).
16. D -58.3 (c = 0.114, MeCN).
17. D.A. Evans, M.D. Ennis, and D.J. Mathre J. Am. Chem. Soc. 104 1982 1737
18. 2 in air. Transfections were performed by the calcium phosphate coprecipitation. Eight hours after transfection, ligands were added. Cells were harvested approximately 16-20 h after the treatment, and luciferase and β-galactosidase activities were assayed using a luminometer and a microplate reader. DNA cotransfection experiments included 50 ng reporter plasmid, 20 ng pCMX-β-galactosidase, 15 ng of each PPAR receptor, and pGEM carrier DNA for a total of 150 ng DNA per well in a 96-well plate. Luciferase data were normalized to an internal β-galactosidase control and represent means (±SD) of triplicate assays.